erlotinib hydrochloride has been researched along with Multiple Primary Neoplasms in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Drpa, G; Kukulj, S; Manojlovic, S; Sreter, KB | 1 |
| Go, H; Hong, BS; Lee, JL; Park, I; Shim, YS | 1 |
| Dietrich, MF; Schiller, JH; Yan, SX | 1 |
| Amano, S; Aoyama, M; Hino, N; Inoue, S; Miyoshi, T; Mori, R; Sumitomo, H; Wada, D | 1 |
| Altavilla, G; Arrigo, C; Pitini, V | 1 |
| Agulnik, M; Guitart, J; Lacouture, ME; Reid, DC | 1 |
| Hansen, KH; Hansen, NC; Hansen, O; Kristiansen, C; Olsen, KE | 1 |
7 other study(ies) available for erlotinib hydrochloride and Multiple Primary Neoplasms
| Article | Year |
|---|---|
Erlotinib for coexisting typical bronchial carcinoid and advanced lung adenocarcinoma: does the epidermal growth factor receptor mutation status matter?
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Bronchial Neoplasms; Carcinoid Tumor; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Protein Kinase Inhibitors | 2018 |
Long-term response of metastatic hereditary leiomyomatosis and renal cell carcinoma syndrome associated renal cell carcinoma to bevacizumab plus erlotinib after temsirolimus and axitinib treatment failures.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Erlotinib Hydrochloride; Humans; Kidney Neoplasms; Leiomyomatosis; Male; Neoplasms, Multiple Primary; Neoplastic Syndromes, Hereditary; Sirolimus; Skin Neoplasms; Time Factors; Treatment Failure; Uterine Neoplasms | 2019 |
Response to Crizotinib/Erlotinib Combination in a Patient with a Primary EGFR-Mutant Adenocarcinoma and a Primary c-met-Amplified Adenocarcinoma of the Lung.
Topics: Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines | 2015 |
Efficacy of erlotinib and imatinib in a patient with a rectal gastrointestinal stromal tumor and synchronous pulmonary adenocarcinoma: A case report.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Erlotinib Hydrochloride; Female; Gastrointestinal Stromal Tumors; Genes, erbB-1; Humans; Imatinib Mesylate; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms, Multiple Primary; Proto-Oncogene Proteins c-kit; Rectal Neoplasms | 2016 |
Erlotinib in a patient with acute myelogenous leukemia and concomitant non-small-cell lung cancer.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasms, Multiple Primary; Quinazolines; Smoking; Tomography, X-Ray Computed | 2008 |
Treatment of multiple keratoacanthomas with erlotinib.
Topics: Aged, 80 and over; Antineoplastic Agents; ErbB Receptors; Erlotinib Hydrochloride; Humans; Immunohistochemistry; Keratoacanthoma; Male; Neoplasms, Multiple Primary; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Skin Neoplasms; Treatment Outcome | 2010 |
Epidermal growth factor receptor mutations in synchronous recurrent lung cancer in an 82-year-old woman. A case story.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemoradiotherapy; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Multimodal Imaging; Mutation; Neoplasm Staging; Neoplasms, Multiple Primary; Positron-Emission Tomography; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Quinazolines; Recurrence; Tomography, X-Ray Computed; Treatment Outcome | 2012 |